November 14 | 2022
2cureX discloses status of 2022 plans, goals for 2023 and its estimates of potential market development in the coming years
Read more
October 11 | 2022
Independent market survey shows great demand for 2cureX product portfolio
Read more
October 6 | 2022
Co-inventor of 2cureX patents awarded Nobel Prize in Chemistry
Read more
September 19 | 2022
Change of distribution partner in Portugal
Read more
September 1 | 2022
2cureX expands distribution of IndiTreat® to Romania
Read more
August 8 | 2022
Kommuniké från extra bolagsstämma i 2cureX
Read more
August 8 | 2022
Announcement from 2cureX extra general meeting
Read more
July 20 | 2022
Notice of extra general meeting in 2cureX AB
Read more
July 20 | 2022
Kallelse till extra bolagsstämma i 2curex AB
Read more
July 1 | 2022
Dr. Raphael Gruber joins 2cureX as new Medical Director
Read more
June 28 | 2022
2cureX expands distribution of IndiTreat® to Israel
Read more
June 7 | 2022
2cureX AB announces share purchase by the company’s Chairman of the Board of Directors and Executive Management
Read more
May 31 | 2022
Strengthening the IndiTreat® distribution in North Europe
Read more
May 24 | 2022
Kommuniké från årsstämma i 2cureX AB
Read more
May 20 | 2022
We invite you to join the 2cureX Q1 Report webcast and Q&A session at 15:00 on 24 May, 2022
Read more
May 17 | 2022
Three IndiTreat® posters have been accepted at ESMO-GI 2022
Read more
May 12 | 2022
2cureX AB nominates Dr. Michael Schaefer to the Board of Directors
Read more
May 12 | 2022
2cureX AB nominerar Dr. Michael Schaefer till styrelsen
Read more